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Introduction: We evaluated the characteristics of thyroid carcinoma in geriatric patients and outcomes
after a 10-years follow-up. Methods: Comparative retrospective study on a group of 31 geriatric patients
and one of 224 non-geriatric, who underwent surgery for thyroid carcinoma in the period 1998e2003.
We compared with Fisher's exact test: histology, multifocality, tumor size, lymph-node metastasis,
distant metastasis, persistence/recurrence and mortality, including and excluding anaplastic carcinomas,
in a subgroup of 26 geriatric patients and another of 223 non-geriatric patients. Results: Results for the
geriatric and non-geriatric groups and in the geriatric and non-geriatric subgroups respectively were as
follows: multifocality 9/31 vs. 74/224 (p-value 0.8382) and 9/26 vs. 74/223 (p-value 1); tumor size: 16/31
vs. 28/224 T3-T4 (p-value < 0.0001) and 11/26 vs. 27/223 T3-T4 (p-value 0.0004); lymph-node metas-
tases: 17/31 vs. 34/224 (p-value < 0.0001) and 12/26 vs. 33/223 (p-value 0.0004); distant metastases: 8/
31 vs. 3/224 (p-value < 0.0001) and 3/26 vs. 2/223 (p-value 0.0088); disease recurrence/persistence: 11/
31 vs. 3/224 (p-value < 0.0001) and 6/26 vs. 2/223 (p-value > 0.0001); mortality: 7/31 vs. 2/224 (p-
value < 0.0001) and 2/26 vs. 1/223 (p-value 0.0295). Anaplastic carcinomas were predominantly in the
geriatric group: 5 vs. 1 (p-value < 0.0001). No statistical differences for other histotypes. Discussion:
Thyroid carcinoma is more aggressive in geriatric patients. This may justify a more aggressive surgical
strategy with possible prophylactic lymphadenectomy, in addition to ablative therapy with 131I and
suppressive therapy with levothyroxine. Conclusion: It would be useful to undertake randomized
prospective studies on a large cohort of patients to determine the most effective therapy for geriatric
patients suffering from thyroid carcinoma.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Carcinomas of the thyroid, in order of prevalence, are divided
into papillary, follicular, medullary, poorly differentiated and
anaplastic carcinomas. Anaplastic carcinomas and those which are
poorly differentiated are neoplasms strictly found in advanced age,
and are very rare in patients under 60 years of age [1e3]. They are
very aggressive cancers with a high mortality rate [4].Well-differ-
entiated carcinomas, on the other hand, are much more frequentroglobulin antibody.
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f of Surgical Associates Ltd.compared to undifferentiated forms and have a good prognosis
with low mortality rates and a survival rate which varies between
80% and 95% [1,5,6].
In well-differentiated carcinomas of the thyroid, age is consid-
ered a quoad vitam prognostic factor [1e3,7e9]. An age between 20
and 44 years old at the time of diagnosis is a favorable prognostic
factor, whereas after 45 years of age, mortality from well-
differentiated carcinomas of the thyroid increases, even if slightly,
and increases in parallel with advancing age [1,7,10]. In geriatric
age, compared to other ages, a signiﬁcant increase in biological
aggressiveness of thyroid cancers has been registered. A deﬁnition
of geriatric age is not unequivocal and has been established arbi-
trarily by several authors, starting from 60 years of age [1e3,11e13].
There are relatively few published studies in the literature
concerning the clinical-pathological characteristics of thyroid can-
cers in geriatric patients and the results of medium to long-term
Table 1
Clinical-pathological characteristics and outcomes of thyroid carcinomas in the
geriatric patient group and the non-geriatric patient group.
Geriatric group
(n ¼ 31)
Non-geriatric group
(n ¼ 224)
Fisher's T. P-
value
Female/Male 22/9 (Ratio 2.44) 167/57 (Ratio 2.93) e
Mean age 70.23 (range 65
e79)
45.51 (range 20e64) e
Anaplastic 5 (16.13%) 1 (0.45%) <0.0001
Papillary 21 (67.74%) 179 (79.91%) 0.1597
Follicular 3 (9.68%) 36 (16.07%) 0.4364
Medullary 2 (6.45%) 8 (3.57%) 0.3485
Unifocality 22 (70.97%) 150 (66.96%) 0.8382
Multifocality 9 (29.03%) 74 (33.04%)
T1eT2 15 (48.39%) 196 (87.5%) <0.0001
T3eT4 16 (51.61%) 28 (12.5%)
Lymph-node
metastases
17 (54.84%) 34 (15.18%) <0.0001
No Lymph-node
metastases
14 (45.16%) 190 (84.82%)
Distant metastases 8 (25.81%) 3 (1.34%) <0.0001
No distant metastases 23 (74.19%) 221 (98.66%)
Disease persistence/
relapse
11 (22.58%) 3 (1.34%) <0.0001
No disease persistence/
relapse
20 (64.52%) 221 (98.66%)
Mortality 7 (22.58%) 2 (0.89%) <0.0001
Survival 24 (77.42%) 222 (99.11%)
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most suitable treatment for this category of patients. On the other
hand, increasing average longevity and aging of the population
have led to and are continuing to affect the rise in the number of
older people, and consequently at the same time the prevalence of
geriatric patients suffering from these pathologies.
Having a good system of post-operative follow-up for patients
who have undergone total thyroidectomy at the Fifth Division of
General Surgery and Special Surgical Techniques at the Second
University of Naples, we wished to evaluate the clinical-
pathological characteristics and the results, after a 10 year follow-
up, of thyroid carcinomas in patients of geriatric age, arbitrarily
choosing 65 years as a cut-off age.
2. Materials and methods
We conducted a retrospective study to evaluate the existence or
not of a correlation between biological aggressiveness of thyroid
cancer and geriatric age.
We selected patients suffering from thyroid cancer who un-
derwent total thyroidectomy, with or without therapeutic lym-
phadenectomy, and ablative therapy with 131I, at the Fifth Division
of General Surgery and Special Surgical Techniques at the Second
University of Naples, in the period between 1st January 1998 and
31st December 2003 and who were subsequently placed in sup-
pressive therapy with levothyroxine. Follow-up was undertaken
with doses of TSH, FT3, FT4, Thyroglobulin (Tg), Thyroglobulin
antibody (Ab-Tg), with a neck scan every 6 months and an annual
chest X-ray and whole-body scintigraphy with 131I.
Inclusion criterion for the study was a minimum follow-up of
ten years, while any patients who were lost during the follow-up
for various reasons other than death for thyroid cancer were
excluded from the study.
The patients included in the study were divided into two groups
on the basis of age: a geriatric group aged 65 years or over, and a
non-geriatric group, under that age limit. Both age and sex were
recorded in the two groups. The following factors were then taken
into consideration for each of the two groups: histological type, the
unifocality or multifocality of the cancer, tumor size (considering
two subgroups: T1eT2 and T3eT4) on the basis of TNM classiﬁ-
cation, the presence or absence of lymph-node metastases, the
presence or absence of distant metastases at the time of diagnosis
[8], the persistence/recurrence of the disease and the mortality rate
linked to cancer of the thyroid.
Each of these parameters were compared separately between
the two groups by means of uni-variate analysis, using the two
tailed Fisher's exact test as a method of statistical analysis. For each
parameter, a null hypothesis H0 would indicate that there is no
correlation between biological aggressive behavior of the cancer
and geriatric age, while the alternative hypothesis, H1, would
indicate that the factor in consideration correlates with geriatric
age prevailing in its most aggressive form. The statistical signiﬁ-
cance (a) adopted was 5%.
To verify that the greatest aggressiveness and the worst prog-
nosis of thyroid carcinomas in geriatric age does not depend on the
greater prevalence of anaplastic carcinomas, patients with
anaplastic carcinomas were subsequently excluded in each group,
thereby creating two subgroups, geriatric and non-geriatric, of
patients suffering from well-differentiated carcinomas of the thy-
roid. After evaluating the age and sex of the patients, each
parameter which was previously taken into consideration was
compared separately again in the two subgroups by uni-variate
analysis, using two tailed Fisher's exact test as a method of statis-
tical analysis to evaluate the existence or not of a correlation be-
tween geriatric age and the biological aggressiveness of well-differentiated carcinomas. Again in these subgroups, for each
parameter, the null hypothesis H0 indicates that there is no cor-
relation between biological aggressiveness of the cancer and geri-
atric age, while the alternative hypothesis, H1, indicates that the
factor in consideration correlates with geriatric age prevailing in its
most aggressive form. The statistical signiﬁcance (a) adopted was
5%.3. Results
There were 296 patients who underwent surgery for thyroid
cancer during the period in question, of whom 38 were geriatric
and 258 non-geriatric. 7 geriatric and 34 non-geriatric patients
were lost during follow-up, and were consequently excluded from
the study. Thus a total of 255 patients were included in the study,
subdivided into a group of 31 geriatric and a group of 224 non-
geriatric patients. The geriatric group consisted of 22 female pa-
tients and 9 male patients with an F/M ratio of 2.44 and an average
age of 70.23 years old (range 65e79). The non-geriatric group
consisted of 167 female patients and 57 male patients with an F/M
ratio of 2.93 and an average age of 45.51 (range 20e64).
As far as the parameters were concerned, on the basis of his-
totypes found, in the geriatric and non-geriatric groups respectively
there were 5 vs. 1 anaplastic carcinomas (P-value < 0.0001); 21 vs.
179 papillary carcinomas (P-value ¼ 0.1597); 3 vs. 36 follicular
carcinomas (P-value¼ 0.4364) and 2 vs. 8 medullary carcinomas (P-
value 0.3485).
In relation to the 6 anaplastic carcinomas, four cases of the ﬁve
geriatric patients presented areas of differentiated papillary tall
cells, probably deriving their origin from the dedifferentiation of a
pre-existing well-differentiated carcinoma, while the other two
anaplastic carcinomas, one in a geriatric patient and the other in a
62 year-old patient, did not present areas of greater differentiation,
suggesting that they originated as anaplastic carcinomas ab initio.
Table 2
Clinical-pathological characteristics and outcomes of differentiated thyroid carci-
nomas in the geriatric patient subgroup and the non-geriatric patient subgroup.
Geriatric subgroup
(n ¼ 26)
Non-geriatric subgroup
(n ¼ 223)
Fisher's T. P-
value
Female/Male 19/7 (Ratio 2.71) 166/57 (Ratio 2.91) e
Eta media 69.61 (Range 65
e76)
45.42 (Range 20e65) e
Unifocality 17 (65.38%) 149 (66.82%) 1
Multifocality 9 (34.62%) 74 (33.18%)
T1eT2 15 (57.69%) 196 (87.89%) 0.0004
T3eT4 11 (42.31%) 27 (12.11%)
Lymph-node
metastases
12 (46.15%) 33 (14.80%) 0.0004
Non lymph-node
metastases
14 (53.85%) 190 (85.20%)
Distant metastases 3 (11.54%) 2 (0.90%) 0.0088
No distant
metastases
23 (88.46%) 221 (99.1%)
Disease persistence/
relapse
6 (23.08%) 2 (0.90%) <0.0001
No disease
persistence/
relapse
20 (76.92%) 221 (99.10%)
Mortality 2 (7.69%) 1 (0.45%) 0.0295
Survival 24 (92.31%) 222 (99.55%)
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geriatric and non-geriatric groups, presented inﬁltration of the pre-
thyroid muscles and of the subcutaneous tissue; in addition two
carcinomas inﬁltrated the peri-tracheal fascia and one inﬁltrated
the right recurrent laryngeal nerve. All of them presented extensive
lymph-node metastases and all six had distant metastases; four in
the lungs, one in the bones and another one in lungs and bones. All
of them showed post-surgical disease persistence and all cases
reached exitus after an average survival of 3.83 months (range 1e6
months).
Regarding the other parameters in consideration, independently
of the histological type, the following results were noted: 22 vs. 150
unifocal carcinomas and 9 vs. 74 multifocal carcinomas (P-
value ¼ 0.8382); 15 vs. 196 T1eT2 cancers and 16 vs. 28 T3eT4
cancers (P-value < 0.0001); 17 vs. 34 cancers with lymph-node
metastases and 14 vs. 190 cancers without lymph-node metasta-
ses (P-value < 0.0001); 8 vs. 3 patients with distant metastases and
23 vs. 221 patients without distant metastases (P-value < 0.0001);
11 vs. 3 cases of recurrence/persistence of the disease and 20 vs. 221
without recurrence/persistence of the disease (P-value < 0.0001)
and 7 vs. 2 cases of death due to progression of the disease (P-
value < 0.0001). The results obtained are reported in Table 1.
The two subgroups with well-differentiated cancers of the
thyroid, obtained by excluding anaplastic carcinomas, were
constituted as follows: the geriatric subgroup of 26 patients (19
female and 7malee F/M ratio of 2.71), with an average age of 69.61
years (range 65e76) and the non-geriatric subgroup of 223 patients
(166 female and 57 male e F/M ratio of 2.91) with an average age of
45.42 years (range 20e64).
The parameters analyzed, which were reconsidered and
compared in the two subgroups (geriatric vs. non-geriatric), pro-
duced the following results: 17 vs.149 unifocal carcinomas and 9 vs.
74 multifocal carcinomas (P-Value ¼ 1); 15 vs. 196 T1eT2 cancers
and 11 vs. 27 T3eT4 cancers (P-value ¼ 0.0004); 12 vs. 33 carci-
nomas with lymph-node metastases and 14 vs. 190 without lymph-
node metastases (P-value ¼ 0.0004); 3 vs. 2 patients with distant
metastases and 23 vs. 221 patients without distant metastases (P-
value 0.0088); 6 vs. 2 patients with recurrence of the disease and 20
vs. 221 without recurrence of the disease (P-value < 0.0001); 2 vs. 1
patients deceased due to progression of the disease (P-
value ¼ 0.0295). These results are reported in Table 2.
Of the geriatric group of patients who died, one patient suffered
from medullary cancer, while the other suffered from sclerosing
papillary carcinoma; they survived 32 and 54 months respectively.
The patient in the non-geriatric group suffered from tall cell
papillary carcinoma and died after 46 months.
Of the three cases with distant metastases in the geriatric group,
two suffered from papillary carcinoma (one with lung metastasis
and the other with bone metastasis) and one from follicular car-
cinoma (with lung metastasis); the two cases in the non-geriatric
group were both follicular carcinomas (both with lung metastases).
Of the six patients with recurrent disease, ﬁve suffered from
papillary carcinoma (recurring with lymph-node metastases in the
neck) and one with follicular carcinoma (recurring with lung me-
tastases). The average length of disease-free time was 42 months
(range 26e59). The two cases of disease recurrence in the non-
geriatric group were for papillary carcinoma and the disease
recurred with lymph-node metastases in the neck after 37 and 49
months respectively.
4. Discussion
The analysis of the results of our study demonstrate that the
prognosis for thyroid carcinomas, 10 years after diagnosis, is worse
in a statistically signiﬁcant manner, in patients of 65 yearscompared to those of younger patients. The all-inclusive mortality
for thyroid cancer was 3.53% (9/255), but the relative percentage of
mortality was 22.58% (7/31) in the geriatric patient group and 0.89%
(2/224) in the non-geriatric group.
In our study, anaplastic carcinoma prevails in geriatric age with
a statistically signiﬁcantly higher frequency, compared to the those
younger patients. There is no statistically signiﬁcant difference,
however, in the prevalence of well-differentiated histotypes, which
has also been demonstrated by other authors [2,3].
Even after considering the exclusion of anaplastic carcinomas,
thyroid carcinomas in geriatric patients presentedmore frequently:
with larger dimensions or extra-glandular extensions, lymph-node
metastases, distant metastases and persistence/recurrence of the
disease. The only parameter which did not show a statistically
signiﬁcant difference between the two groups was multifocality.
Ultimately, therefore, age represents an unfavorable prognostic
factor in patients suffering from carcinoma of the thyroid, inde-
pendently of the histological type.
Fully or only partly in line with our results, several authors have
found, at the time of diagnosis, a larger dimension of thyroid car-
cinoma, a higher frequency of lymph-node and distant metastases
and persistence/recurrence of the disease in geriatric patients
[1e3,10]. These parameters, according to TNM classiﬁcation, esti-
mate the extent of the disease at the time of diagnosis, but it is
necessary to seek, apart from these factors in which there may be
an epiphenomenon of greater aggressiveness of the thyroid carci-
noma, biological factors intrinsic to cellular carcinomatous cell,
which are able to confer a greater growth potential and capacity for
distant metastasis. Two of these biological factors which have been
identiﬁed so far are BRAFV600E and TERTC228T mutations, which
correlate with a worse prognosis [14,15].
Apart from surgical treatment, in carcinoma of the thyroid, other
non-surgical adjuvant or alternative treatments exist such as radio-
metabolic therapy with 131I, suppressive therapy with levothyrox-
ine and external radiotherapy.
Several studies have demonstrated that in carcinoma of the
thyroid, the greater the extent of surgical treatment (lobectomy,
G. Santangelo et al. / International Journal of Surgery 12 (2014) S103eS107S106partial resection, total thyroidectomy or therapeutic lymphade-
nectomy) the better the results in terms of survival [1,16,17]. On the
one hand, it is unquestionable that the risk from surgery in geriatric
patients is greater than in non-geriatric patients in virtue of the fact
that there are more frequent co-morbidities with a subsequent
increase in complications of a general nature [18,19]. On the other
hand, several studies have demonstrated that the number of
complications speciﬁcally linked to thyroid surgery in geriatric
patients is essentially superimposable on those of younger patients
[11e13,20]: in consideration of the nature of the pathologies
examined, this may justify more aggressive surgical approaches or
at the very least notmore restricted compared to those set down for
younger patients.
Concerning ablative therapy with 131I, in geriatric patients, apart
from a greater potential for growth and metastasis of thyroid car-
cinoma, a reduction in uptake of 131I has been found on the part of
both the primitive tumor and the recurrent lesions, which conse-
quently render post-surgical ablative radio-metabolic therapy less
effective [1,6,21].
Some authors have reported evidence that external radio-
therapy exercises a certain control over the local disease and a
prevention of loco-regional recurrence, which may be associated
with a lengthening of the survival period [22e24].
As far as suppressive therapy with levothyroxine is concerned, a
related risk is represented by the fact that it is associated with an
increased risk of arrhythmia and of osteoporosis [7,25]. However,
the conﬁrmed aggressiveness of thyroid cancer in geriatric patients
may justify the use of this therapy, although it requires more
frequent cardiological and osteo-metabolic examinations, and
should only be used in the absence of absolute contraindications.
The recurrence of the illness, both in some of the patients
enrolled in our study and in those of other authors, has been found
to happen suddenly after a disease-free period of variable length
[1,18]. It is probable that at the time of surgical treatment there
were metabolically inert micro-metastases present in a state of
quiescence known as dormancy and therefore unable to uptake 131I
[26e29]. Subsequently, such cells, via cellesignaling, which is not
yet well-understood, may have “re-awoken”, leading to a recur-
rence of the tumor and to progression of the disease [26,28,29]. On
the basis of this evidence, post-surgical ablative radio-metabolic
therapy and suppressive therapy with levothyroxine undoubtedly
represent essential post-surgical treatments.
Nevertheless, in particular we should examine the role of the
extent of surgical treatment. Regarding surgical treatment, in
consideration of the fact that more extensive surgery corresponds
to a greater survival rate, and considering that in geriatric patients
ablative radio-metabolic therapy with 131I has been found to be less
effective, it may be hypothesized that more aggressive surgery
compared to total thyroidectomy with therapeutic lymphadenec-
tomy would lead to a better survival rate: Such a hypothesis would
require randomized prospective studies with a large cohort of pa-
tients to evaluate the effects of total thyroidectomy associated with
prophylactic ipsilateral latero-cervical lymphadenectomy and
central compartment prophylactic lymphadenectomy to assess the
prevalence of lymph-node micro-metastases, not revealed by
clinical-instrumental examination nor by surgical exploration, in
order to evaluate the impact of this approach on survival and
morbidity.
Such a consideration should now be extended to anaplastic
carcinomas. In fact, recent studies have demonstrated longer sur-
vival rates compared to the past [4,24] and additionally evidence
exists, obtained by in vitro experiments, of the effectiveness of
certain drugs which exert on the one hand a cytoreductive effect on
anaplastic clones, and on the other hand which favors re-
differentiation, inducing the reacquisition of the ability to uptake131I [30e34]: this may render the clones susceptible to radio-
metabolic therapy with 131I. In addition, the loss of anaplasia,
may also render them less resistant to external radiotherapy. These
two factors would lend more weight in justifying the use of the
more aggressive surgical approach of de-bulking, in order to in-
crease the effectiveness of adjuvant treatment, especially if in vivo
studies produced results superimposable to those obtained by
in vitro studies.
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